Multiple endocrine neoplasia type 2 historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Historical Perspective== | ==Historical Perspective== | ||
* It has been speculated that Abraham Lincoln had MEN 2B given his tall stature, lesions on his lips, weight loss and shape of his head <ref>http://www.msnbc.msn.com/id/30267859/</ref> | * It has been speculated that Abraham Lincoln had MEN 2B given his tall stature, lesions on his lips, weight loss and shape of his head <ref>http://www.msnbc.msn.com/id/30267859/</ref> | ||
* In 1954 Wermer noted that this [[syndrome]] was transmitted as a dominant trait. | |||
* In 1959 Hazard ''et al.'' described medullary (solid) [[thyroid carcinoma]]. | |||
* In 1961 Sipple described a combination of a [[pheochromocytoma]], [[medullary thyroid carcinoma]] and [[parathyroid adenoma]]. | |||
* In 1966 Williams ''et al.'' described the combination of mucosal neuromas, [[pheochromocytoma]] and [[medullary thyroid carcinoma]]. | |||
* In 1968 Steiner ''et al.'' introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of [[endocrine]] [[tumor]]s and proposed the terms '[[Wermer syndrome]]' for MEN 1 and '[[Sipple syndrome]]' for MEN 2. | |||
* In 1974 Sizemore ''et al.'' showed that the MEN 2 category included two groups of patients with MTC and [[pheochromocytoma]]: one with [[parathyroid]] [[disease]] and a normal appearance (MEN 2A) and the other without [[parathyroid]] [[disease]] but with mucosal neuromas and mesodermal abnormalities ([[MEN 2B]]). | |||
* In 1993, RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes. | * In 1993, RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes. | ||
* In 1998 the MEN1 gene was cloned<ref name="Guru1998">Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the [[multiple endocrine neoplasia type 1]] (MEN1) gene. ''J Intern Med'' 243(6) 433-9</ref> | |||
==References== | ==References== | ||
Revision as of 01:59, 21 September 2015
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 historical perspective On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 historical perspective |
|
FDA on Multiple endocrine neoplasia type 2 historical perspective |
|
CDC on Multiple endocrine neoplasia type 2 historical perspective |
|
Multiple endocrine neoplasia type 2 historical perspective in the news |
|
Blogs on Multiple endocrine neoplasia type 2 historical perspective |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
|
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Historical Perspective
- It has been speculated that Abraham Lincoln had MEN 2B given his tall stature, lesions on his lips, weight loss and shape of his head [1]
- In 1954 Wermer noted that this syndrome was transmitted as a dominant trait.
- In 1959 Hazard et al. described medullary (solid) thyroid carcinoma.
- In 1961 Sipple described a combination of a pheochromocytoma, medullary thyroid carcinoma and parathyroid adenoma.
- In 1966 Williams et al. described the combination of mucosal neuromas, pheochromocytoma and medullary thyroid carcinoma.
- In 1968 Steiner et al. introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors and proposed the terms 'Wermer syndrome' for MEN 1 and 'Sipple syndrome' for MEN 2.
- In 1974 Sizemore et al. showed that the MEN 2 category included two groups of patients with MTC and pheochromocytoma: one with parathyroid disease and a normal appearance (MEN 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B).
- In 1993, RET germline mutations were recognized as the causative molecular alterations in MEN 2 syndromes.
- In 1998 the MEN1 gene was cloned[2]
References
- ↑ http://www.msnbc.msn.com/id/30267859/
- ↑ Guru SC, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. J Intern Med 243(6) 433-9